Literature DB >> 23983951

Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients.

Paul Fallon, Serdar Dursun, Bill Deakin.   

Abstract

BACKGROUND: An association between abnormal involuntary movements and psychotic relapse was previously reported in a group of patients compliant with antipsychotic medication (Fallon and Dursun 2011). This was interpreted as the presence of an antipsychotic medication-induced supersensitivity psychosis.
METHOD: From the results of that study and the Chouinard diagnostic criteria for supersensitivity psychosis an abbreviated diagnostic checklist was developed to identify the phenomenon. In the present study the checklist was used on a larger sample of medication-compliant individuals experiencing a psychotic relapse.
RESULTS: The checklist demonstrated its utility by identifying a cause of relapse in 70% (29/41) of patients. Furthermore, it identified the presence of supersensitivity psychosis in 39% (16/41) of patients. This study also replicated a number of findings from the previous paper supporting the idea that supersensitivity psychosis is one cause of relapse in psychosis. DISCUSSION: These results suggested that clinicians should exercise caution in prescribing and may have to augment treatment with other agents or switch to low dopamine-affinity antipsychotics.

Entities:  

Keywords:  diagnostic checklist; relapse; supersensitivity psychosis

Year:  2012        PMID: 23983951      PMCID: PMC3736929          DOI: 10.1177/2045125311431105

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  14 in total

Review 1.  Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature.

Authors:  G R Marland; V Sharkey
Journal:  J Adv Nurs       Date:  1999-12       Impact factor: 3.187

2.  Causes and consequences of duration of untreated psychosis in schizophrenia.

Authors:  R J Drake; C J Haley; S Akhtar; S W Lewis
Journal:  Br J Psychiatry       Date:  2000-12       Impact factor: 9.319

3.  Remission and relapse in psychosis: operational definitions based on case-note data.

Authors:  Paul E Bebbington; Tom Craig; Philippa Garety; David Fowler; Graham Dunn; Susannah Colbert; Miriam Fornells-Ambrojo; Elizabeth Kuipers
Journal:  Psychol Med       Date:  2006-08-16       Impact factor: 7.723

4.  A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis.

Authors:  Paul Fallon; Serdar M Dursun
Journal:  J Psychopharmacol       Date:  2010-02-10       Impact factor: 4.153

5.  Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.

Authors:  G Chouinard
Journal:  Schizophr Res       Date:  1991 Jul-Aug       Impact factor: 4.939

6.  Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

Authors:  L Voruganti; L Cortese; L Oyewumi; Z Cernovsky; S Zirul; A Awad
Journal:  Schizophr Res       Date:  2000-06-16       Impact factor: 4.939

7.  Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.

Authors:  M B Knable; A Heinz; T Raedler; D R Weinberger
Journal:  Psychiatry Res       Date:  1997-09-29       Impact factor: 3.222

8.  The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment.

Authors:  G E Hogarty; R F Ulrich
Journal:  J Psychiatr Res       Date:  1998 May-Aug       Impact factor: 4.791

9.  The influence of life events on the subsequent course of psychotic illness. A prospective follow-up of the Camberwell Collaborative Psychosis Study.

Authors:  J van Os; T A Fahy; P Bebbington; P Jones; S Wilkins; P Sham; A Russell; K Gilvarry; S Lewis; B Toone
Journal:  Psychol Med       Date:  1994-05       Impact factor: 7.723

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  12 in total

Review 1.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Authors:  Martin Harrow; Thomas H Jobe; Robert N Faull; Jie Yang
Journal:  Psychiatry Res       Date:  2017-06-22       Impact factor: 3.222

Review 3.  Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.

Authors:  Yasunori Oda; Nobuhisa Kanahara; Masaomi Iyo
Journal:  Int J Mol Sci       Date:  2015-12-17       Impact factor: 5.923

4.  Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.

Authors:  Masayuki Takase; Nobuhisa Kanahara; Yasunori Oda; Hiroshi Kimura; Hiroyuki Watanabe; Masaomi Iyo
Journal:  J Psychopharmacol       Date:  2015-03-03       Impact factor: 4.153

5.  Supersensitivity psychosis and its response to asenapine in a patient with delusional disorder.

Authors:  Ravi Philip Rajkumar
Journal:  Case Rep Psychiatry       Date:  2014-11-13

6.  Late-Onset Mania in a Patient with Movement Disorder and Basal Ganglia Calcifications: A Challenge for Diagnosis and Treatment.

Authors:  Beatrice Roiter; Giorgio Pigato; Giulio Perugi
Journal:  Case Rep Psychiatry       Date:  2016-04-24

7.  Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases.

Authors:  Katsumasa Muneoka; Nobuhisa Kanahara; Shou Kimura
Journal:  SAGE Open Med Case Rep       Date:  2017-02-08

Review 8.  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Felice Iasevoli
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 9.  Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.

Authors:  John Yin; Alasdair M Barr; Alfredo Ramos-Miguel; Ric M Procyshyn
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity.

Authors:  Anna Kruyer; Jeffrey Parrilla-Carrero; Courtney Powell; Lasse Brandt; Stefan Gutwinski; Ariana Angelis; Reda M Chalhoub; Thomas C Jhou; Peter W Kalivas; Davide Amato
Journal:  Mol Psychiatry       Date:  2021-08-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.